Malignant prostatic carcinoma, a major cause of cancer mortality in males, most often metastasizes to secondary sites in bone. Frequently, the growth rate of the secondary tumor in bone marrow is considerably greater than that of the slowly growing primary prostatic tumor. We now report that two lines of human prostatic carcinoma cells proliferate in response to conditioned media from unstimulated human, rat, or bovine bone marrow. Nonprostatic tumor cell lines showed little or no growth response to the same medium.
Introduction
Prostatic adenocarcinoma is a slow-growing tumor that afflicts > 50% of the male population over the age of 70 (1) . Although only a small percentage of prostatic tumors reach sufficient size to escape from the primary site, metastatic prostate tumors are associated with a high mortality rate and represent a leading cause of cancer deaths among males (2, 3) . Prostatic carcinoma metastases are most commonly found in bone marrow, where their growth rate appears to be considerably more rapid than that observed for primary prostatic tumors (4, 5) . That certain tissues may provide a preferential environment for the growth of certain tumors was first proposed by Paget in 1889 (6) . According to this theory, the osteotropism of prostatic carcinoma cells could result if these cells were particularly responsive to growth factors present in bone marrow.
Bone marrow is the major site of hematopoietic cell growth. It exists as two clearly identifiable components: the hematopoietic cells that make up the majority of the cellular elements and the stromal component that is formed of highly vascular connective tissue (7) . The hematopoietic cells are transient in the marrow; upon maturation they move into the blood stream. The stroma, however, remains and serves as a scaffolding upon which the hematopoietic cells can differentiate and mature. The stromal cells in the marrow cavity produce a number of hematopoietic growth factors (HGFs'; [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ; several such colony-stimulating factors (CSFs) have been purified, sequenced, and cloned (23) (24) (25) (26) (27) (28) . Furthermore, growth factors produced outside the marrow cavity can be sequestered and concentrated in the bone marrow after binding to extracellular matrix elements in the marrow stroma (29) .
In this study, we have investigated whether factors present in bone marrow can stimulate the growth of metastatic prostatic carcinoma cells that selectively colonize the bone marrow. Our results demonstrate that bone marrow-conditioned medium (BMCM) stimulates the growth of prostatic carcinoma cells but not of a variety of other tumor cell types. We also show that bone marrow stromal cell-conditioned medium greatly enhances the growth of prostatic carcinoma cells. This activity is not duplicated by any of a variety of known growth factors and may consequently represent the action of a novel mitogenic agent.
Methods
Cell lines. All cell lines were obtained from the American Type Culture Collection, Rockville, MD. PC-3 cells (human prostate adenocarcinoma, derived from bone marrow metastases) were grown in RPMI medium 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% defined FCS (Hyclone Laboratories, Logan, UT), 0.3 mg/ml glutamine, 100 U/ml penicillin, and 100 ug/ml streptomycin (Irvine Scientific, Santa Ana, CA). Serum was heat-treated for 30 min at 560C before use. DU 145 cells (human prostate carcinoma, derived from a brain metastasis in a patient with wide-spread metastatic disease) were grown in DME (Gibco Laboratories) supplemented with 10% FCS, glutamine, and antibiotics as were SK-Mel-2 cells (human malignant melanoma, metastatic to skin of thigh), CAKI-l cells (human kidney carcinoma, metastatic to skin), MCF-7 cells (human breast carcinoma, pleural effusion), Calu-l cells (human lung epidermoid carcinoma, metastatic to pleura), SK-N-MC cells (human neuroblastoma, metastatic to supra orbital area), and Hs 746t cells (human stomach carcinoma, metastatic to leg). MDA-MB-361 cells (human breast adenocarcinoma, metastatic to brain) were grown in L-15 medium (Gibco Laboratories) with 10% FCS, glutamine, and antibiotics.
Preparation of BMCM. Marrow was obtained by cutting bone fragments with sterile bone clippers and gently scraping out the red or yellow marrow fraction. The bones were then rinsed with 5-10 ml of RPMI 1640 medium that was then added to the marrow. The marrow contents were suspended by gentle pipetting with a 10-ml sterile plastic pipette. The marrow cells were then centrifuged at 700 g for 5 min, and resuspended in 1-2 ml of serum-free RPMI medium containing glutamine, penicillin, and streptomycin. The suspension was incubated in 5% CO2 for 24 h at 370C. The resulting BMCM was clarified by centrifugation at 800 g for 5 min to remove cells and frozen at -20'C. Protein concentrations in the marrow-conditioned media were determined using a protein assay (Bio-Rad Laboratories, Richmond, CA). The protein concentration ofthe BMCM ranged from 0.5-1.2 mg/ml. For cell growth assays, the conditioned medium was thawed and diluted with sterile RPMI 1640 medium.
BMCM was prepared from human, bovine, and rat bones. Bovine clavicles were kindly furnished by the New Boston Food Market, South Boston, MA. The clavicles were first rinsed with 10% Betadyne solution and marrow was then processed. Rat marrow,'obtained by flushing the femurs of 175-200-g Sprague-Dawley male rats (Charles River Breeding Laboratories, Wilmington, MA) with 2 ml of PBS was treated in the same manner described above. Human bone samples, kindly provided by Dr. Robert Shamberger, Children's Hospital of Boston, were obtained from sternal fragments normally removed in the process of correction of pectus excavatum deformity. These bone samples were the source for red marrow. Yellow marrow was obtained from a healthy femur that was-amputated as a consequence of peripheral vascular disease. In each case, the collected marrow was suspended in I ml of medium and BMCM was obtained as described above.
Bone Preparation of conditioned medium from other human organs. Organ tissue was minced into I mm3 fragments and washed with 5 ml of RPMI 1640 medium. The organ tissue was suspended by gently pipetting with a 5-ml sterile plastic pipet and then centrifuged at 700 g for 5 min. The wash medium was discarded and the organ tissue resuspended in 1-2 ml of serum-free RPMI medium containing glutamine, penicillin and streptomycin. The conditioned medium was then prepared as described in the previous section.
All tissue samples were kindly provided by Dr. Mark Litwin, Brigham and Women's Hospital, Boston. Kidney tissue was obtained from a nephral ureterectomy for ureteral carcinoma; skeletal muscle, from a prostatectomy for benign prostatic hyperplasia; and foreskin tissue, from a cosmetic circumcision procedure.
Growthfactors. The properties of the recombinant HGFs have been described in detail previously (23) (24) (25) (26) (27) (28) (29) (30) (31) . All of the hematopoietic factors were generously provided by Dr. Steven C. Clark, Genetics Institute, Cambridge, MA, with the exception of IL 1, 2, and 4, which were from Genzyme Corp., Boston, MA. Recombinant human macrophage-colony stimulating factor (M-CSF) and granulocyte-macrophage-CSF (GM-CSF) were expressed in Chinese hamster ovary (CHO) cells engineered to release high levels of the factors into culture medium. Assays were conducted using M-CSF that was partially purified (-50% pure) and GM-CSF that was highly purified (> 95% pure) from the CHOconditioned medium. The partially purified M-CSF preparations stimulated half of the maximal level of murine macrophage colony formation at a dilution of 1:300,000. Highly purified GM-CSF had a specific activity of 1-4 X 106 U/mg when assayed for the ability to stimulate proliferation of primary blasts from patients with chronic myelogenous leukemia (CML).
Recombinant G-CSF and IL 3 were expressed in monkey cos cells. Cos cell-conditioned medium containing G-CSF stimulated human granulocyte colony formation with half-maximal activity at a dilution of 1:100,000. Assays for IL 3 activity were conducted using nonfractionated IL 3 containing cos cell-conditioned medium or with IL 3 that had been purified to near homogeneity from this medium. The nonfractionated material stimulated half-maximal proliferation of CML blasts at a dilution of 1:100,000 whereas the purified IL 3 had a specific activity of 2 X I07 U/mg when tested in the same assay. Mock conditioned media from non-transfected CHO cells or cos cells were used as controls. IL 1-6 were tested as cos cell-conditioned medium and displayed half-maximal activity on murine bone marrow colony formation at a dilution of 1:10,000. IL 1 was purified from monocytes that had been stimulated with heat-killed Staphylococcus albus. The IL 1 preparations contained 8 X 106 U of activity per gg of protein where one unit is the amount required to double the proliferative response of mouse thymocytes after stimulation with 1 ug/ml of PHA. Transforming growth factor beta (TGF-beta), from fresh human or porcine platelets, was purchased from R & D Systems, Inc., Minneapolis, MN.
The half-maximal activities for the stimulation of colorky formation in soft agar has been determined to be 1 ng/ml for AKR-2B fibroblasts and 0.1-0.4 ng/ml for normal rat kidney (NRK) (49F) fibroblasts. This preparation was found to be at least 97% pure by NH2-terminus analysis and analysis on silver-stained gels. Transforming growth factor alpha (TGF-alpha), purchased from Creative BioMolecules, Hopkinton, MA, was expressed in Escherichia coli and determined to be 99% pure by reverse phase HPLC. Maximal activity was determined to be -0.05 ng/ml in mouse 3T3 cells. Epidermal growth factor (EGF) and basic fibroblast growth factor (b-FGF) were purchased from AMGen Biologicals, Thousand Oaks, CA. EGF was prepared from an E. coli host recombinant DNA procedure and purified to 98% purity by sequential chromatography. The half-maximal specific activity was found to be 0.1 ng/ml in NRK cells. bFGF was prepared by recombinant DNA procedures in E. coli and found to be at least 95% pure by sequential chromatography. The half-maximal specific activity, determined by [3H]thymidine uptake by mouse 3T3 fibroblasts, was 20-50 pg/ml. Acidic fibroblast growth factor (a-FGF) was kindly provided by Dr. Patricia D'Amore, Children's Hospital, Boston. a-FGF was purified to a single band on silver-stained gels and confirmed by Western blot analysis. One unit was defined as the half maximal activity, determined by [3H]thymidine incorporation by mouse 3T3 fibroblasts. Purified platelet-derived growth factor (PDGF) was kindly provided by Dr. Harry Antoniades, Center for Blood Research, Boston. The purified PDGF was obtained from clinically outdated human platelets and prepared as described (32 
Results
BMCM stimulates prostatic adenocarcinoma cell growth. To determine whether factors derived from human bone marrow could support the growth of prostatic carcinoma cells, PC-3 human prostatic carcinoma cells were incubated for 4 d in culture medium containing 1% FCS and increasing concentrations of human BMCM. As shown in Fig. 1 , increasing concentrations of BMCM effectively stimulated PC-3 cell proliferation in a dose-dependent fashion. Maximal proliferation was seen at a protein concentration of 30 gg/ml with halfmaximal activity at 15 ,ug/ml. As a control, conditioned medium made from other human organs was tested at the same doses. The skin, muscle, and kidney had little or no effect on the growth of the prostatic carcinoma cells. When incubated with BMCM prepared from yellow marrow, the prostatic carcinoma cells showed no significant response (data not shown). The kinetics of cell growth were determined in a separate experiment shown in Fig. 2 showed a significantly smaller response (20 and 37% increase, respectively) than that observed with either ofthe prostatic cell lines. Cell lines that showed a modest response relative to the prostatic cell lines included the MDA-MB-361 (human breast adenocarcinoma cells, metastatic to brain, 40%), Sk-N-MC (human neuroblastoma, metastatic to supra-orbital area, 36%), and Hs 746T (human stomach carcinoma, metastatic to leg, 38%). Whereas the background growth ofthe different cell types in 1.0% calf serum varied considerably, the two prostatic tumor cell lines represent both extremes of the spectrum, with PC-3 cells displaying slow background growth and DU 145 displaying rapid background growth; yet, both cell types showed markedly increased growth in the presence of the marrow-conditioned medium. Although no individual cultured cell line can be considered completely representative of its in vivo counterpart, the results described above strongly suggest that prostatic carcinoma cells are more highly respon- sive to bone marrow-derived growth factors than any of the other types of metastatic tumor cells tested.
Effect ofgrowth factors on the proliferation ofprostatic carcinoma cells. Bone marrow is the major site of proliferation of hematopoietic cells and mesenchymal cells in the marrow cavity have been shown to produce a variety of HGFs (8, 30, 36) . We therefore investigated whether any of the known HGFs could be responsible for the proliferative stimulation of prostatic carcinoma cells. Six human recombinant HGFs were tested alone and in a variety of combinations to determine if they had possessed any mitogenic activity for PC-3 cells. These included IL 1, IL 2, IL 3, IL 4, IL 6, G-CSF, M-CSF, and GM-CSF. When tested alone (Table I) , none of the factors demonstrated any substantial proliferative activity on the prostatic carcinoma cells. A modest but significant increase in cell number was noted when M-CSF was added to the culture medium. This increase is, however, only 15% of that observed with BMCM. Endotoxin, a potential contaminant ofthe bone marrow conditioned medium could account for < 5% of the proliferative activity present in BMCM.
We also tested a number of nonhematopoietic growth factors to see whether they could stimulate the prostatic carcinoma cells as well as the BMCM. As shown previously (32) (33) (34) (35) , neither EGF, basic or acidic FGF, PDGF, or insulin had any effect on the growth of prostatic carcinoma cells. TGF-beta has been shown to be stimulatory for cells ofmesen- (31, (38) (39) (40) (41) (42) (43) (44) . To determine whether combinations of hematopoietic factors would promote an increased stimulation of prostatic carcinoma cell growth, we incubated PC-3 cells with mixtures of two or more factors. No dramatic increase in cell growth was seen when G-CSF, M-CSF, GM-CSF, and IL 3 were combined in all possible combinations of two factors (Fig. 4) . However, when combinations of three factors were tested, the combination of G-CSF, IL 3, and M-CSF produced a significant increase in cell growth. The addition of IL 1, IL 2, IL 3, IL 4, IL 6, or GM-CSF to this combination did not increase the proliferative response (data not shown). Mock conditioned media from nontransfected CHO or cos cells did not contain significant proliferative activity for PC-3 cells when tested in appropriate dilutions and combinations. The above results demonstrate that combinations of HGFs display proliferative activity for prostatic carcinoma cells. Note, however, that the increase in cell growth observed with the combination ofthree HGFs is < 30% ofthat observed when cells are incubated with BMCM for the same time period. In addition, bioassays demonstrate that these three factors are not present in significant levels in our BMCM (data not shown). Thus while these experiments show that it is possible for HGFs to act in combination to promote nonhematopoietic cell growth, the hematopoietic factors tested are not responsible for the rapid growth of prostatic carcinoma cells in bone marrow.
Effects ofbone marrow stromal cell-conditioned medium. Data obtained from in vitro studies of long-term bone marrow cultures have shown that stromal cell conditioned medium contains diffusible factors that can modify the proliferative activity ofstem cells (21) . We therefore tested human bone marrow stromal cell-conditioned medium for growth-promoting activity on the prostatic carcinoma cells. Our results, shown in Table II , demonstrate that cloned human marrow stromal cells release growth factors with significant mitogenic activity for prostatic carcinoma cells equivalent to that found in crude BMCM. This result implies that the predominant mitogenic activity in BMCM is contributed by the stromal cell population.
Comparative mitogenic activity of BMCM derived from different species and different bone sites. To determine whether the marrow-derived activity was species specific, we prepared BMCM from bovine clavicles and from rat femurs and compared the mitogenic activity of these factors with that of the human sternal marrow. As shown in Fig. 5 , growth-stimulating activity for PC-3 cells was found in all three marrow preparations with greatest activity seen in the bovine material. These results demonstrate that the ability to support PC-3 cell proliferation is a property of bone marrow from a variety of species as well as from different bone sites.
Discussion
It has long been appreciated that certain human tumors metastasize preferentially to particular organs (6) . The reasons for such specificity are many and include: (a) mechanical factors such as proximity or ease of access of tumor cells to a particular site (45) (49) (50) (51) .
It is now well established that these mechanisms are not mutually exclusive and that the successful colonization of a given organ by a given tumor cell type will generally involve a com- Prostatic carcinomas most frequently metastasize to cancellous bone, with greatest frequency to central sites such as the spine, pelvis, femur, and ribs (4, 5) . It has long been thought that this process is facilitated by the existence of specialized channels first described by Batson (57, 58) that run between the prostate and the spine. The possibility that controls on cell growth might also influence the pattern of prostatic cancer metastasis is suggested by the fact that primary prostatic tumors grow extremely slowly over the course of 30-40 yr before exiting the primary site, yet metastatic prostate tumors grow rapidly in secondary bone sites. Thus, although the ratio of metastatic to nonmetastatic prostatic tumors is quite low (< 5%), the metastatic tumors that do become established grow rapidly and account for a significant mortality among older males (3) .
It has been suggested that products of resorbing bone can stimulate growth and chemotaxis of bone-seeking tumors (59, 60) . This may apply to tumors such as the Walker rat carcinoma, human neuroblastomas, and human mammary carcinomas that cause lytic bone degradation at the site of secondary tumor growth. Prostatic tumors, on the other hand, rarely cause osteolysis and are more frequently associated with osteosclerosis or the build-up of bone mass (5) . For such osteosclerotic tumors, the presence of bone resorption products should be minimal and consequently, other factors in bone marrow might be expected to play a more direct role in the establishment of metastases to bone. We therefore tested products ofhuman, rat, and bovine bone marrow for their ability to stimulate the proliferation of various human tumor lines. Our results demonstrate that bone marrow-derived factors markedly stimulate the proliferation oftwo human cell lines derived from prostatic cancer metastases, the PC-3 and DU-145 cell lines. Cell lines derived from other human tumors with differing metastatic preferences showed a significantly lower response to the bone marrow-derived mitogens. These results demonstrate the presence of mitogenic factors for prostatic carcinoma cells in normal bone marrow and suggest that such factors may influence the enhanced growth rate displayed by prostatic carcinoma cells that have metastasized to secondary bone sites.
Because bone marrow is the major site of hematopoiesis, we inquired whether any ofthe known HGFs not only had the capacity to stimulate hematopoietic cell proliferation but also resulted in increased growth of human prostatic carcinoma cells. No dramatic proliferative activity for PC-3 cells was noted when IL 1, IL 2, IL 3, IL 4, IL 6, G-CSF, M-CSF, or GM-CSF were tested alone or in combinations of two factors. Only the addition of the three HGFs M-CSF, G-CSF, and IL 3 caused an increase in PC-3 cell growth. Although it is of interest that combinations of HGFs stimulate prostatic carcinoma cell growth, these particular factors cannot be responsible for the mitogenic activity observed in BMCM for the following reasons: (a) the proliferative response seen with this combination of HGFs was considerably lower than that observed with the BMCM; (b) significant amounts of M-CSF, G-CSF, and IL-3 were not detected by bioassay of our BMCM; and (c) activity for human prostatic carcinoma cells was found in rat BMCM even though rodent IL 3 has no activity on human cells (24) . Thus, although our results demonstrate that some combinations of HGFs can stimulate prostatic carcinoma cell growth, they do not imply that these particular factors are responsible for the activity observed in BMCM.
A number of nonhematopoietic growth factors have been shown to have growth promoting activity on cells of epithelial or mesenchymal origin. These factors include EGF, acidic and basic FGF, PDGF, and insulin (61). When we tested these factors on the human prostatic carcinoma cells, we found that they had no significant mitogenic effect. Transforming growth factors are polypeptides that promote phenotypic transformation of normal mammalian cells; TGF-alpha is a potent mitogen, whereas TGF-beta is inhibitory for epithelial cells. In our experiments, TGF-alpha had no stimulatory effect on the prostatic carcinoma cells and TGF-beta proved to be inhibitory.
Little is known about the nature ofthe interaction between hematopoietic cells and their supporting stroma. It is not clear whether the stromal cells are merely acting as a supportive matrix providing a privileged site for hematopoiesis to occur or whether the stromal cells themselves play a role in determining cell lineage development within the hematopoietic system (22 
